Abiopharma

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001213900-26-094805 <b>Size:</b> 622 KB

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001918704-26-025290 <b>Size:</b> 688 KB

(85% Positive) IBIO, INC. (IBIO) Reports Q3 2026 Financial Results

(99% Neutral) INVO FERTILITY, INC. (IVF) Files Form 8-K

(99% Positive) APREA THERAPEUTICS, INC. (APRE) Announces Enrollment Update for options Due to Patient Enrollment Issues, Regulatory Process, Safety Review

(99% Neutral) UNIFIRST CORP (UNF) Announces Executive Departure

Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference

Leifras Celebrates 25th Anniversary, Setting Vision for Becoming Global Infrastructure Through "Sports and Social"

Novavaxs Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

The Arena Group d/b/a Paradium.AI Completes Name Change, Will Trade Under New Stock Ticker PAAI Effective August 31, 2026

FangDD Reports First Half 2026 Unaudited Financial Results

Critical Metals Corp. Provides Update on Proposed Acquisition of European Lithium

Special Committee of Better Home &amp; Finance Urges Shareholders to Reject Former CEO Vishal Garg’s Campaign to Seize Control of the Company

INVO Fertility to Participate in H.C. Wainwrights 28th Annual Global Investment Conference

Wellchange Holdings Company Limited Announces Pricing of $7.5 Million Public Offering of its Class A Ordinary Shares